At http://www.qualitystocks.net/ you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.
We would like to highlight TapImmune Inc. (OTCBB: TPIM). The company is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, TAP vaccine, performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, or Transporters Associated with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.
TapImmune Inc. recently announced that an independent third-party research group published an article in the Journal of Investigative Dermatology confirming that a TapImmune (TAP) vaccine should be considered as a therapy for treating melanoma-based cancer. The National Cancer Institute has forecast that, within the next five years, cancer will be ranked as the number one cause of death of Americans.
The company’s TAP vaccine against cancer helps the body move cancer makers to the surface of cells to allow a person’s body to detect and fight the cancerous cells. Initially developed at The University of British Columbia, the preclinical trials for melanoma and lung carcinoma in animal subjects show positive results. A 70% survival rate was achieved in test subjects when using the TAP vaccine therapy, while a 100% survival rate was achieved when the TAP was administered ex-vivo.
The TAP vaccine has also shown success in acting as an ‘accelerant’ to enhance the potency of vaccines against infectious diseases. When the TAP vaccine was incorporated in a smallpox vaccine, the results showed an increased potency of between 100 to 1000 times. As of today, there is only one FDA-approved accelerant available for use on humans. With the growing number of infectious diseases, the ability to increase the effectiveness of primary vaccine inoculations is essential.
Recent estimates show that traditional cancer treatments, such as chemotherapy, represent a $10 billion market. The global vaccine market is now estimated at $13 billion, with projected growth to $21 billion by 2010. Accordingly, cancer vaccines represent a $135 million market with expected growth to more than $6 billion by 2010. Now that TapImmune has completed its preclinical testing, the company is ready to enter into the regulated development phase for its vaccine. Based upon its current testing position, the company should be able to generate revenues from sales and royalty streams by 2014.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
